Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study-Reference-Cited by-同舟云学术

Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study

Published:2023-09 Issue: Volume:74 Page:15-21
ISSN:0924-977X
Container-title:European Neuropsychopharmacology
language:en
Short-container-title:European Neuropsychopharmacology

Author:

Chiappini Stefania^ORCID,d'Andrea Giacomo^ORCID,De Filippis Sergio,Di Nicola Marco,Andriola Ileana,Bassetti Roberta,Barlati Stefano^ORCID,Pettorruso Mauro,Sensi Stefano^ORCID,Clerici Massimo,Dell'Osso Bernardo,Vita Antonio,Martinotti Giovanni

Publisher

Elsevier BV

Subject

Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,Neurology (clinical),Neurology,Pharmacology

Reference19 articles.

1. Results of the European Group for the Study of Resistant Depression (GSRD) - basis for further research and clinical practice;Bartova;World J. Biol. Psychiatry,2019

2. Treatment-resistant depression as risk factor for substance use disorders-a nation-wide register-based cohort study;Brenner;Addiction,2019

3. Substance use disorders and risk for treatment resistant depression: a population-based, nested case-control study;Brenner;Addiction,2020

4. Current and common definitions of treatment-resistant depression: findings from a systematic review and qualitative interviews;Brown;Can. J. Psychiatry,2019

5. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence;Frank;Arch. Gen. Psychiatry,1991

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring vortioxetine combination with intranasal esketamine: A feasible alternative to SSRI/SNRI? - Insights from the REAL-ESK study;Journal of Affective Disorders;2024-12

2. Benefits and risks of esketamine nasal spray continuation in treatment-resistant depression;Biomarkers in Neuropsychiatry;2024-12

3. A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists;Journal of Affective Disorders;2024-10

4. Ketamine treatment for anhedonia in unipolar and bipolar depression: a systematic review;European Neuropsychopharmacology;2024-09

5. The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS);Journal of Affective Disorders;2024-09